Expertise in
3
conditions

Chieh-lung Cheng

No. 7, Chung Shan South Road, 
TPQ, TW 
Expertise in
3
conditions
No. 7, Chung Shan South Road, 
TPQ, TW 

Overview

Chieh-lung Cheng practices practicing medicine in Taiwan.

Cheng is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Hepatitis.

They are actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 7, Chung Shan South Road, TPQ 10002, Taiwan
Other Locations
No. 7, Chung Shan South Road, 100, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)
A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)
Enrollment Status: Terminated
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drug: Lenalidomide+Gemcitabine
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

23 Total Publications

Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.
Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations.
Journal: Blood research
Published: January 01, 2026

Frequently Asked Questions about Chieh-lung Cheng

Is Chieh-lung Cheng a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Chieh-lung Cheng is classified as an Advanced expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chieh-lung Cheng participate in research or clinical trials?

Yes. Chieh-lung Cheng has published 23 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Chieh-lung Cheng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cheng's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile